Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Public ClinicalTrials.gov record NCT01316874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.
Study identification
- NCT ID
- NCT01316874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1993 (Type not available)
- Primary completion
- Apr 1997 (Actual)
- Completion
- Apr 1997 (Actual)
- Last update posted
- Jun 12, 2015
1993 – 1997
United States locations
- U.S. sites
- 39
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stacy Childs, MD | Alabaster | Alabama | — | — |
| William Bohnert, MD | Phoenix | Arizona | — | — |
| Scott Swanson, MD | Scottsdale | Arizona | — | — |
| Bruce Dalkin, MD | Tucson | Arizona | — | — |
| Donald Gleason, MD | Tucson | Arizona | — | — |
| William Friedel, MD | La Mesa | California | — | — |
| Stephen Auerbach, MD | Newport Beach | California | — | — |
| William Moseley, MD | San Diego | California | — | — |
| Standley Brosman, MD | Santa Monica | California | — | — |
| Eugene Dula, MD | Van Nuys | California | — | — |
| B. Thomas Brown, MD | Daytona Beach | Florida | — | — |
| Charles Jackson, MD | Fort Lauderdale | Florida | — | — |
| Marc Soloway, MD | Miami | Florida | — | — |
| Charles Brendler, MD | Chicago | Illinois | — | — |
| Patrick Guinan, MD | Chicago | Illinois | — | — |
| Jeffrey Ignatoff, MD | Evanston | Illinois | — | — |
| David Wood, MD | Lexington | Kentucky | — | — |
| John Tuttle, MD | Lexington | Kentucky | — | — |
| Dennis Venable, MD | Shreveport | Louisiana | — | — |
| Harold Frazier, MD | Bethasda | Maryland | — | — |
| Myron Murdock, MD | Greenbelt | Maryland | — | — |
| John Libertino | Burlington | Massachusetts | — | — |
| W. Lamar Weems, MD | Jackson | Mississippi | — | — |
| Hugh Fisher, MD | Albany | New York | — | — |
| Michael Blute, MD | Rochester | New York | — | — |
| Michael Wolff, MD | Burlington | North Carolina | — | — |
| Cary Robertson, MD | Durham | North Carolina | — | — |
| Eric Klein, MD | Cleveland | Ohio | — | — |
| Bruce Lowe, MD | Portland | Oregon | — | — |
| Jeffrey Cohen, MD | Pittsburgh | Pennsylvania | — | — |
| Jacques Susset, MD | Providence | Rhode Island | — | — |
| L. Dean Knoll, MD | Nashville | Tennessee | — | — |
| Steohen Hardeman, MD | Austin | Texas | — | — |
| Ian Thompson, MD | Fort San Houston | Texas | — | — |
| Seth Lemer, MD | Houston | Texas | — | — |
| Aaron Katz, MD | Richmond | Virginia | — | — |
| Gary Katz, MD | Richmond | Virginia | — | — |
| Williams Ellis, MD | Seattle | Washington | — | — |
| Richard Boxer, MD | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01316874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01316874 live on ClinicalTrials.gov.